U.S. FDA approves atogepant for adults with chronic migraine
The U.S. Food and Drug Administration (FDA) has approved expanding the indication of AbbVie’s QULIPTA (atogepant) for the preventive treatment of migraine in adults. The approval makes QULIPTA the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist approved to prevent episodic and chronic migraine. People living with chronic migraine experience headaches for 15 or […]
